Shortage of Trulicity (dulaglutide)
Solution for injection in pre-filled pens (0.75, 1.5, 3 and 4.5 mg)

| **Indication** | Trulicity is a medicine used in addition to diet and exercise in adults and children from 10 years of age who have type 2 diabetes. It is used: • on its own when use of metformin (another medicine for type 2 diabetes) is not recommended; • as an ‘add-on’ to other diabetes medicines. |
| **Reason for shortage** | There has been an increase in demand for Trulicity, which has led to intermittent supply shortages. These are expected to continue at least until the end of 2024 in most affected EU Member States. The supply shortage is not related to a quality defect of the product or a safety issue. |
| **Member States affected** | Austria, Belgium, Finland, Hungary, Italy, Netherlands, Portugal, Spain and Sweden are currently affected or are at risk of being affected by the shortage. This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, contact the national competent authority. |
| **Monitoring of shortage** | EMA’s SPOC working party is closely monitoring the supply situation and engaging with the marketing authorisation holder and other stakeholders to identify measures to mitigate the impact of the supply shortage. |
| **Information for healthcare professionals** | • An increase in demand for Trulicity has led to intermittent supply shortages that are expected to... |

---

1 This document was initially published on 28 August 2023. It was then modified on 16 October 2023 and 24 June 2024 to update information on the duration of the shortage.
2 The SPOC working party is responsible for monitoring and reporting events that could affect the supply of medicines in the EU. Summaries of the SPOC working party meetings can be found on EMA’s website.
**Shortage of Trulicity (dulaglutide)**
**Solution for injection in pre-filled pens (0.75, 1.5, 3 and 4.5 mg)**

*continue at least until the end of 2024 in most affected EU Member States.*
*Healthcare professionals should ensure that patients at risk of running out of Trulicity are switched in time to a suitable alternative.*
*For additional information, consult your country’s [national shortage register](#) or [national competent authority](#).*

### Information for patients

- An increase in demand for Trulicity has led to intermittent supply shortages that are expected to continue at least until the end of 2024 in most affected EU Member States.
- If you are at risk of running out of Trulicity, your doctor will discuss with you the need to switch to a suitable alternative.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s [national shortage register](#) or [national competent authority](#).

### Status

Ongoing